APLASTIK ANEMIYANI DAVOLASHDA IMMUNOSUPRESSIV TERAPIYA VA SUYAK ILIGI TRANSPLANTATSIYASINING SAMARADORLIGINI TAHLIL QILISH.

Authors

  • Mahliyo A. Alisherova Toshkent davlat tibbiyot universiteti, Tibbiy radiologiya kafedrasi assistenti
  • Usmonov Sherzodbek Toshkent davlat tibbiyot universiteti, Davolash fakulteti talabasi

Keywords:

aplastik anemiya, immunosupressiv terapiya, suyak iligi transplantatsiyasi, antitimotsit globulin, eltrombopag, haploidentik transplantatsiya, gematopoetik ildiz hujayralari.

Abstract

Aplastik anemiya (AA) – suyak iligi yetishmovchiligi, periferik qonda pansitopeniya va suyak iligining giposellulyarligi bilan tavsiflanadigan kam uchraydigan, ammo hayot uchun xavfli patologiyadir. Ushbu maqolada AAning patogenezi, epidemiologiyasi va zamonaviy davolash strategiyalari atroflicha tahlil qilingan. Statistik ma’lumotlarga ko‘ra, kasallanish darajasi Osiyo mamlakatlarida (yiliga 100 000 aholiga 0,39–0,50) Amerika va Yevropaga (0,23) nisbatan sezilarli darajada yuqoridir. Maqolaning asosiy maqsadi immunosupressiv terapiya (IST) va allogen gematopoetik ildiz hujayralari transplantatsiyasi (HSCT) ning klinik samaradorligini qiyosiy baholashdan iborat. Tahlillar shuni ko‘rsatadiki, IST (ATG + siklosporin) tarkibiga eltrombopagning qo‘shilishi terapevtik javobni 80% gacha oshiradi. Biroq, 40 yoshgacha bo‘lgan bemorlarda HLA-mos birodar donordan o‘tkazilgan HSCT 90-95% gacha omon qolish ko‘rsatkichini ta’minlovchi yagona kurativ usul bo‘lib qolmoqda. Shuningdek, maqolada haploidentik transplantatsiya (haplo-HSCT) va gen terapiyasi kabi yangi yo‘nalishlarning istiqbollari muhokama qilinadi.

References

Young N.S. Aplastic Anemia. New England Journal of Medicine. 2018; 379(17): 1643-1656. doi: 10.1056/NEJMra1413485.

Marsh J.C., et al. Guidelines for the diagnosis and management of aplastic anaemia. British Journal of Haematology. 2009; 147(1): 43-70. )

Global Burden of Disease 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet. 2020; 396(10258): 1204-1222.

Peslak S.A., et al. Diagnosis and Treatment of Aplastic Anemia. Current Treatment Options in Oncology. 2017; 18(12): 70.

Killick S.B., et al. Guidelines for the diagnosis and management of adult aplastic anaemia. British Journal of Haematology. 2016; 172(2): 187-207. doi: 10.1111/bjh.13853.

Samarasinghe S., et al. Diagnosis and management of acquired aplastic anemia in childhood. Pediatric Blood & Cancer. 2018; 65(8): e27046.

Jayakumar, J., Ginjupalli, M., Vojjala, N., Turku, D., Khan, F., Thannir, S., Babu, A. K., Rajarajan, S., Mathew, T. A., & Roy, A. M. (2025). Racial disparities in the management of deep vein thrombosis from a nationwide hospitalization study. Blood Advances, 9(17), 4364–4367. https://doi.org/10.1182/bloodadvances.2025016171

Kastritis, E., Solia, I., Malandrakis, P., Theodorakakou, F., Ntanasis-Stathopoulos, I., Kanellias, N., Fotiou, D., Migkou, M., Eleutherakis-Papaiakovou, E., Spiliopoulou, V., Kokkali, N., Papanikolaou, A., Giannouli, S., Gavriatopoulou, M., Terpos, E., & Dimopoulos, M. A. (2025). Patterns of progression among 427 patients with smoldering myeloma diagnosed after 2014: importance of monitoring. Blood Advances, 9(17), 4444–4447. https://doi.org/10.1182/bloodadvances.2025016083

Fattizzo, B., Gurnari, C., Giammarco, S., Ricchiuti, A., Awada, H., Bortolotti, M., Galli, N., Pedone, G. L., Versino, F., Consonni, D., Trikha, R., Gandhi, S., Sica, S., Maciejewski, J. P., Kulasekararaj, A., & Barcellini, W. (2025). Elderly patients with aplastic anemia: Treatment patterns and outcomes in the real world. American Journal of Hematology, 100(4), 584–591. https://doi.org/10.1002/ajh.27611

Wirk B. Acquired aplastic anemia therapies: immunosuppressive therapy versus alternative donor hematopoietic cell transplantation. Journal of Hematology. 2024;13(3):61-70. doi:10.14740/jh1264

Sheng, T., Sun, W., Xin, S., Zhou, C., & Liu, H. (2026). Efficacy and mechanism of action of sovleplenib for aplastic anemia. Hematology, 31(1), 2618419. https://doi.org/10.1080/16078454.2026.2618419

Sun, Z., Hong, Y., Hong, Y., Xin, C., Liu, Q., Hu, H., Shen, Y., Chen, Y., Liu, S., Shen, Y., Zhou, Y., & Wu, D. (2026). Peripheral versus Marrow Lipidomics in Patients with Severe Aplastic Anemia: Potential Indicators for Early Immunosuppressive Treatment Response. Lipids. https://doi.org/10.1002/lipd.70034

Sharma, A. (2025). Future directions in transplantation for aplastic anemia. Hematology, 2025(1), 691–698. https://doi.org/10.1182/hematology.2025000767

Sun Z, Hong Y, Hong Y, et al. Peripheral versus Marrow Lipidomics in Patients with Severe Aplastic Anemia: Potential Indicators for Early Immunosuppressive Treatment Response. Lipids. Published online January 19, 2026. doi:10.1002/lipd.70034

Jalaeikhoo H, Khajeh-Mehrizi A. Immunosuppressive Therapy in Patients with Aplastic Anemia: A Single-Center Retrospective Study. PLoS ONE. 2015;10(5):e0126925. doi:10.1371/journal.pone.0126925

Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood. 2012;120(6):1185-1196.

Peffault de Latour R, Kulasekararaj A, Iacobelli S, et al. Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia. N Engl J Med. 2022;386(1):11-23. doi:10.1056/NEJMoa2109965

Gurnari C, et al. Management of elderly patients with aplastic anemia. Hematology Am Soc Hematol Educ Program. 2023.

Risitano AM, et al. In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing. Lancet. 2004;364(9431):355-364. doi:10.1016/S0140-6736(04)16724-X

Yoshizato T, et al. (yuqoridagi 2015 yilgi NEJM maqolasi); Babushok DV, et al. Emergence of clonal hematopoiesis in the majority of patients with acquired aplastic anemia. Cancer Genet. 2015;208(4):115-128.

Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag for refractory aplastic anemia. N Engl J Med. 2012;367(1):11-19; Townsley DM, et al.

Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia. N Engl J Med. 2017;376(16):1540-1550. doi:10.1056/NEJMoa1613878

Grunenwald A, et al. HCAR2 is a novel receptor for heme. Blood Advances. 2025;9(17):4459-4470. GPCR skriningi (241 ta), HCAR2 gem retseptori, SPR, Hcar2/Hmox1 korrelyatsiyasi, HO-1 inhibisyonu

Fattizzo B, et al. Elderly Patients With Aplastic Anemia: Treatment Patterns and Outcomes in the Real-World Era. American Journal of Hematology. 2025; (nashrda). 1113 bemor (319 keksa), davolash javobi, omonat qolish, MDS evolyutsiya, transplantatsiya natijalari, klinik algoritm

Sheng T, Sun W, Xin S, Zhou C, Liu H. Efficacy and mechanism of action of sovleplenib for aplastic anemia. Hematology. 2026;31(1):2618419. AA sichqon modeli, sovleplenib (SYK inhibitori), CD4⁺/CD8⁺ nisbati, M1/M2 makrofag, cGAS-STING-NF-κB yo‘li

Global Burden of Disease Study 2021. Stroke statistics. Lancet Neurol. 2024;23(5):456-468.Bacigalupo A. How I treat acquired aplastic anemia. Blood. 2017;129(11):1428-1436. doi:10.1182/blood-2016-08-693481

Killick SB, Bown N, Cavenagh J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016;172(2):187-207.

Liu L, Han B, Zhang Y, et al. First-line treatment of severe aplastic anemia: immunosuppressive therapy plus eltrombopag versus haploidentical hematopoietic stem cell transplantation, a multicenter prospective study. Bone Marrow Transplant. 2024;59(3):342-349.

Piekarska A, et al. The state of the art in the treatment of severe aplastic anemia: immunotherapy and hematopoietic cell transplantation in children and adults. Front Immunol. 2024;15:1345678.

Hong Y, Liu Q, Sun Z, et al. Efficacy and safety of hematopoietic stem cell transplantation vs. immunosuppressive therapy in patients with hepatitis-associated aplastic anemia: a systematic review and meta-analysis. Hematology. 2025;30(1):1-12.

Xu ZL, Xu LP, Zhang XH, et al. Haploidentical hematopoietic stem cell transplantation for severe aplastic anemia: a multicenter study from China. Am J Hematol. 2020;95(5):E112-E115.

Downloads

Published

2026-05-05